Articles: sars-cov-2.
-
J Microbiol Immunol Infect · Jun 2020
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
-
Chronic Dis Transl Med · Jun 2020
Expert recommendations on blood purification treatment protocol for patients with severe COVID-19.
Coronavirus disease (COVID-19) was first diagnosed in Wuhan in December 2019. The World Health Organization defined the subsequent outbreak of COVID-19 worldwide as a public health emergency of international concern. Epidemiological data indicate that at least 20% of COVID-19 patients have severe disease. ⋯ The third step is to monitor and adjust parameters of blood purification. The fourth step is to evaluate the timing of discontinuation of blood purification. It is expected that blood purification will play a key role in effectively reducing the mortality of patients with severe COVID-19 through the standardized implementation of the present protocol.
-
Emerging Infect. Dis. · Jun 2020
Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020.
Since early January 2020, after the outbreak of coronavirus infection in Wuhan, China, ≈365 confirmed cases have been reported in Shenzhen, China. The mode of community and intrafamily transmission is threatening residents in Shenzhen. Strategies to strengthen prevention and interruption of these transmissions should be urgently addressed.
-
Information regarding the incidence and characteristics of COVID-19 pneumonia amongst pregnant women is scarce. ⋯ Instituto de Salud Carlos III (COV20/00,181), Spanish Ministry of Science and Innovation.